Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 5Lymphoid 3Plasma cell 2Other neoplasm 2Other hematologic neoplasm 2Myeloid 2Gastrointestinal 2Sarcoma 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 180Cisplatin 157Radiotherapy 78Carboplatin 71Radiotherapy, Intensity-Modulated 69Cetuximab 66Magnetic Resonance Spectroscopy 64Nivolumab 63Paclitaxel 52Docetaxel 50Specimen Handling 45Radiation 35Gemcitabine 33Fluorouracil 31Surveys and Questionnaires 28Biopsy 27toripalimab 26Drug Therapy 26Platinum 25Surgical Procedures, Operative 24Standard of Care 231,2-diaminocyclohexaneplatinum II citrate 23cemiplimab 22atezolizumab 21Capecitabine 20Ipilimumab 19Chemoradiotherapy 19durvalumab 18Taxes 17Immune Checkpoint Inhibitors 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Patient Reported Outcome Measures × Head & Neck × 1 year × Clear all
NCT04146064 2026-05-08

Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response

University Health Network, Toronto

Completed
190 enrolled
DermatologicGenitourinaryHead & Neck

Carcinoma, Transitional Cell, Head and Neck Neoplasms, Kidney Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡